Skip to content 
Crosslinked Povidone (Crospovidone) as a Superdisintegrant: Disintegration Mechanism and Its Correlation with Disintegration Time
In oral solid dosage forms, rapid tablet disintegration is a critical step to ensure timely drug release and absorption. Among various superdisintegrants, crosslinked povidone (Crospovidone, or PVPP) is widely used due to its fast action, high swelling capacity, and compatibility with a broad range of active pharmaceutical ingredients (APIs).
This article explores the disintegration mechanism of crospovidone and examines how its structure and concentration affect disintegration time, helping formulators optimize performance in immediate-release tablets.
1. What is Crosslinked Povidone (Crospovidone)?
Crospovidone is a water-insoluble but highly swellable polymer, chemically described as a crosslinked version of polyvinylpyrrolidone (PVP). Due to its rigid, non-gel-forming matrix, crospovidone swells rapidly upon water uptake without forming a viscous barrier, making it ideal for fast disintegration.
Key features:
High capillary activity
No gel formation
Excellent physical and chemical stability
Compatible with both direct compression and wet granulation
2. Disintegration Mechanism of Crospovidone
Crospovidone works via a combination of mechanisms:
Swelling Effect: Upon contact with water, it rapidly swells, creating internal pressure within the tablet.
Wicking Action (Capillary Activity): Its porous structure draws water into the tablet core, initiating disintegration.
Particle Expansion and Deformation: The expansion of individual particles disrupts the tablet matrix from within.
These mechanisms act synergistically to produce very fast disintegration, usually within 30 to 60 seconds, even at low concentrations (2–5%).
3. Correlation Between Crospovidone Concentration and Disintegration Time
| Crospovidone Concentration (% w/w) | Average Disintegration Time (Seconds) | Observations |
|---|---|---|
| 2% | 45–60 | Adequate for small tablets |
| 4% | 30–45 | Optimal balance for most IR tablets |
| 6% | 25–35 | Rapid disintegration but risk of over-compression |
| >8% | Minimal benefit, may affect hardness | Diminishing returns |
Key insights:
Higher concentrations reduce disintegration time, but the effect plateaus after ~6%.
Excessive levels may interfere with tablet hardness and friability.
Disintegration is also influenced by tablet size, compression force, and other excipients.
4. Factors Influencing Crospovidone’s Performance
Particle size and grade: Smaller particles offer faster water uptake.
API solubility: High-solubility APIs may mask the effect of disintegrants.
Compression force: Too much pressure can reduce porosity and delay disintegration.
Co-formulated excipients: Hydrophobic excipients can hinder water penetration, reducing efficiency.
Proper excipient compatibility screening and tablet robustness testing are essential for maximizing crospovidone’s effectiveness.
5. Case Example: Formulation with Crospovidone vs. Other Superdisintegrants
| Superdisintegrant | Typical Use Level | Disintegration Time | Remarks |
|---|---|---|---|
| Crospovidone | 2–5% | 25–45 sec | Fast, non-gelling |
| Sodium Starch Glycolate | 2–8% | 30–90 sec | May form gel layer at high levels |
| Croscarmellose Sodium | 2–5% | 30–60 sec | Effective but may be slower than crospovidone |
Crospovidone consistently offers faster disintegration and low sensitivity to tablet hardness, making it a preferred choice for high-speed production lines.
Conclusion
Crospovidone’s rapid swelling and strong capillary activity make it a powerful disintegrant for immediate-release formulations. By understanding its mechanism of action and how its concentration correlates with disintegration time, formulators can fine-tune tablet performance for optimal bioavailability and patient compliance.
